Joanna L Kaplan

Joanna L Kaplan

Assistant Professor

Medicine & Epidemiology


Licenses
State of California Veterinary Medical Licensure
State of Iowa Limited Specialty Veterinary Medical Licensure
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
Education
2007, Study Abroad, Goucher College, Roatan, Honduras
2008, Study Abroad, University of East Anglia, Norwich, UK
2009, BA, Goucher College, Towson, MD
2015, DVM, University of California, School of Veterinary Medicine, Davis, California
2024, PhD, University of California, Davis, California
Active Research Grants
Principal Investigator, 2024 ACVIM Pacemaker Grant: Safety and efficacy of dual antithrombotic therapy with clopidogrel and rivaroxaban versus clopidogrel and apixaban in healthy cats, (Principal Investigator), American College of Veterinary Internal Medicine
Most Recent Five Book Chapters
2022 Kaplan JL, Stern JA: Canine Cardiomyopathy, Silverstein DC and Hopper K, (ed), Small Animal Critical Care Medicine (3rd edition), Philadelphia. .
Research Focus
Cardiology
Ten Recent Publications

2024
Rivas VN, Vandewege MW, Ueda Y, Kaplan JL, Reader J, Roberts JA, Stern JA
Transcriptomic and genetic profiling in a spontaneous non-human primate model of hypertrophic cardiomyopathy and sudden cardiac death.

2024
Rivas VN, Crofton AE, Jauregui CE, Wouters JR, Yang BS, Wittenburg LA, Kaplan JL, Hwee DT, Murphy AN, Morgan BP, Malik FI, Harris SP, Stern JA
Cardiac myosin inhibitor, CK-586, minimally reduces systolic function and ameliorates obstruction in feline hypertrophic cardiomyopathy

2023
Rivas VN, Kaplan JL, Kennedy SA, Fitzgerald S, Crofton AE, Farrell A, Grubb L, Grigorean G, Jauregui CE, Choi E, Harris SP, Stern JA
Multi-omic, histopathologic, and clinicopathologic effects of once-weekly oral rapamycin in a naturally occurring feline model of hypertrophic cardiomyopathy

2023
Bannasch DL, Oertle DT, Vo J, Batcher KL, Stern JA, Kaplan JL, Li RHL, Madden IE, Christen M, Leeb T, Joshi N
Naturally occurring canine laminopathy leading to a dilated and fibrosing cardiomyopathy in the Nova Scotia Duck Tolling Retriever

2023
Kaplan JL, Rivas VN, Connolly DJ
Advancing treatments for feline hypertrophic cardiomyopathy (HCM): the role of animal models and targeted therapeutics

2023
Kaplan JL, Rivas VN, Walker AL, Grubb L, Farrell A, Fitzgerald S, Kennedy S, Jauregui CE, Crofton AE, McLaughlin C, Van Zile R, DeFrancesco TC, Meurs KM, Stern JA
Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial

2023
Sharpe AN, Oldach MS, Kaplan JL, Rivas V, Kovacs SL, Hwee DT, Morgan BP, Malik FI, Harris SP, Stern JA
Pharmacokinetics of a single dose of Aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model.

2023
Stern JA, Rivas VN, Kaplan JL, Ueda Y, Oldach MS, Ontiveros ES, Kooiker KB, van Dijk SJ, Harris SP
Hypertrophic cardiomyopathy in purpose-bred cats with the A31P mutation in cardiac myosin binding protein-C.

2023
Sharpe AN, Oldach MS, Rivas VN, Kaplan JL, Walker AL, Kovacs SL, Hwee DT, Cremin P, Morgan BP, Malik FI, Harris SP, Stern JA
Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy.

2023
Ellis-Reis RE, Visser LC, Hsue W, Sharpe AN, Kaplan JL
Echocardiographic evaluation of regurgitant fraction in dogs with subclinical myxomatous mitral valve disease: Method comparison, effects of pimobendan, and reproducibility.